Neuroendocrine prostate cancer is an aggressive and increasingly recognized resistance phenotype arising in advanced prostate adenocarcinoma, particularly after prolonged androgen receptor-directed therapy. The gene discussed is AR; the disease is prostate adenocarcinoma.